মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →ইঙ্গিত ও ব্যবহার
Dabiren is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days. ... Read moreDabiren is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days. To reduce the risk of recurrence of DVT and PE in patients who have been previously treated. For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery.
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
Reduction in the risk of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: For patients with CrCl >30 mL/min: 150 mg orally, twice daily For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily Treatment of DVT and PE: For patients with CrCl >30 mL/min: 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation.Reduction in the Risk of Recurrence of DVT and PE: For patients with CrCl >30 mL/min: 150 mg orally,twice daily after previous treatment.Prophylaxis of DVT and PE Following Hip Replacement Surgery: For patients with CrCl >30 mL/min: 110 mg orally first day, then 220 mg once daily. Temporarily discontinue Dabigatran Etexilate Mesylate before invasive or surgical procedures when possible, then restart promptly.Pediatric Use: Safety and effectiveness of Dabigatran Etexilate in pediatric patients have not been established.Geriatric Use: Of the total number of patients in the RE-LY study, 82% were 65 and over, while 40% were 75 and over. The risk of stroke and bleeding increases with age, but the risk-benefit profile is favorable in all age groups.
পার্শ্বপ্রতিক্রিয়া
Premature discontinuation of Dabiren Etexilate increases the risk of thrombotic events. Dabiren Etexilate increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Common side effects of Dabiren Etexilate include indigestion, upset stomach, or burning, stomach pain. In some people Dabiren Etexilate can cause symptoms of an allergic reaction.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Premature discontinuation of Dabiren Etexilate increases the risk of thrombotic events. Dabiren Etexilate increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Epidural or spinal hematomas may occur in patients treated with Dabiren Etexilate who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. The use of Dabiren Etexilate is contraindicated in patients with mechanical prosthetic valves. The concomitant use of Dabiren Etexilate with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. For patients with triple-positive antiphospholipid syndrome, treatment with Dabiren Etexilate increases the risk of thrombosis.
নিষেধাজ্ঞা
Dabigatran Etexilate is contraindicated in patients with active pathological bleeding, patients with history ofserious hypersensitivity reaction to Dabigatran Etexilate and patients with mechanical prosthetic heart valve.